Join the fight. Learn more about our clinical trial.
Every day researchers are working to discover new information about lymphoma and its treatment. Our research can only happen because people like you choose to participate in clinical trials. With your help we can learn more, and continue the development of potential new cancer treatments.
The ECHELON-2 clinical trial is an ongoing study for people with certain kinds of newly diagnosed T-cell non-Hodgkin lymphoma (T-cell lymphoma). This study is being conducted to determine whether brentuximab vedotin, an investigational drug, is safe and effective for the treatment of newly diagnosed patients who have not previously received chemotherapy for T-cell lymphoma.
Brentuximab vedotin has been studied in hematologic (blood-related) cancers in later lines of patient treatment. It is approved in select countries for the treatment of specific hematologic cancers after the failure of previous therapies, however its use in newly diagnosed T-cell lymphoma patients is strictly investigational. Therefore, it is important for patients to learn more about the study and fully consider potential risks and benefits of study participation.
This study may be an option if you are:
- 18 or older
- Have not yet started chemotherapy treatment for lymphoma
- Have been recently diagnosed with T-cell lymphoma such as:
- Anaplastic large cell lymphoma (ALCL)
- Peripheral T-cell lymphoma (PTCL)
- Angioimmunoblastic T-cell lymphoma (AITL)
- Adult T-cell leukemia/lymphoma (ATLL)
- Enteropathy-associated T-cell lymphoma (EATL)
- Hepatosplenic T-cell lymphoma (HSTCL)
The ECHELON-2 study is for patients with CD30-positive tumors. You may or may not know if your tumor is CD30-positive. This is ok. Your CD30 status will need to be assessed by a physician. Learn more about lymphoma and CD30.